Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes common thyroid disorders in a β-thalassemia patient with frequent blood transfusions, emphasizing the need for monitoring thyroid function in such patients.

In this study, both physician and patient reports revealed that more severe alopecia areata was associated with higher emotional symptoms and greater activity limitations among patients.

This study found that daily treatment with ritlecitinib 50 mg over 24 months reduced the number of patients in the highest categories of scalp hair loss, with improvements seen in patient responses over time.

This study found that calcipotriol scalp solution was more effective than a coal tar-based shampoo for treating mild to moderate scalp psoriasis and showed continued efficacy with long-term use.

This case report describes a 39-year-old woman whose dermatomyositis-systemic lupus erythematosus overlap syndrome symptoms resolved after switching to tofacitinib.

This report discusses a case of hair toe tourniquet syndrome in an infant and emphasizes the importance of early diagnosis and treatment to prevent severe complications.

This review discusses hairstyling practices in the black community linked to traction alopecia, categorizes them by risk, and offers guidance for dermatologists on management and patient education but reports no new clinical results.

Most patients with Tuberous sclerosis had neurological or skin issues, and over half had psychiatric problems.

This study found that a significant number of boreal woodland caribou in NE British Columbia showed symptoms of trace mineral deficiencies and exposure to various pathogens, with substantial winter tick infestations affecting a majority of individuals.

Suplatast tosilate successfully treated a woman's systemic sclerosis symptoms.

Mutations in the TSPEAR gene cause a new form of ectodermal dysplasia affecting hair and tooth development.

This study found that intralesional triamcinolone acetonide injections effectively increased hair density in African American women with traction alopecia, showing promise as a safe treatment option.

This study found that using planimetric surface area measurement might be a useful supplementary method to improve the accuracy of SALT scoring in alopecia areata, particularly for scores S1 to S3.

In this open-label trial, Tofacitinib was well tolerated and improved IFN and cytokine scores, as well as overall skin pathology, in individuals with Down syndrome and immune skin conditions.

CTA is often mistaken for AA but doesn't respond to steroids and may require hair transplantation.

A woman's hair grew back while she was taking sulphasalazine for arthritis.

In this study, certain haircare practices and age factors were found to be associated with the occurrence and severity of traction alopecia among women in Yaoundé.

This case report documented successful full hair regrowth in an 8-year-old with alopecia universalis after oral tofacitinib treatment, but mild headaches led to discontinuation.

In this report, two young patients with corticosteroid-refractory alopecia totalis experienced safety and efficacy from oral tacrolimus.

In this retrospective study, oral tofacitinib treatment for at least 6 months improved scalp hair loss in 69.1% of alopecia areata patients, with patchy AA cases responding better compared to other subtypes, and no significant adverse effects were reported.

This study reported that six out of seven pediatric patients with refractory patchy alopecia areata experienced significant hair regrowth after one month of oral tofacitinib treatment, suggesting it may be an effective and safe option, although larger studies are needed to evaluate long-term safety.

Tanshinone IIA helps protect skin tissue from low oxygen damage by boosting certain cell markers.

This retrospective study evaluated the use of tofacitinib as an induction therapy for severe alopecia areata and found it promising and comparable to the standard oral mini-pulse treatment, though pulse steroids may be considered if tofacitinib response is inadequate.

This study found that tofacitinib is an effective and more tolerable treatment than systemic corticosteroids for moderate-to-severe alopecia areata, and its combination with corticosteroids may offer improved efficacy.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.

This study highlights that traumatic anserine folliculosis is a benign condition often seen in young males, which can be diagnosed without invasive biopsies using clinical examination and dermoscopy.

Sulfasalazine might cause hair loss, especially in women, and stopping it can reverse the hair loss.